Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forty Seven Inc stock logo
FTSV
Forty Seven
$95.51
$95.51
$5.53
$95.51
$4.60B0.41.61 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$98.18
+1.6%
$83.40
$60.40
$106.83
$18.63B0.92.28 million shs3.24 million shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.75
-3.0%
$0.69
$0.53
$7.11
$121.74M0.32.56 million shs539,756 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$22.90
-3.3%
$24.81
$11.16
$27.64
$1.06B0.48901,739 shs504,334 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$13.34
-2.3%
$12.27
$9.03
$17.70
$929.57M1.19580,854 shs363,270 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forty Seven Inc stock logo
FTSV
Forty Seven
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
0.00%-0.32%+1.34%+43.18%+34.31%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
0.00%+1.66%+12.55%-20.43%-88.35%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-1.31%-6.34%-6.76%+12.59%
Zymeworks Inc. stock logo
ZYME
Zymeworks
0.00%+3.93%+1.83%+25.49%+44.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forty Seven Inc stock logo
FTSV
Forty Seven
N/AN/AN/AN/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
4.3684 of 5 stars
3.54.00.04.32.21.70.6
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
4.7491 of 5 stars
4.14.00.03.42.90.81.9
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.1022 of 5 stars
2.21.00.03.92.02.50.6
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.9185 of 5 stars
3.54.00.00.01.83.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forty Seven Inc stock logo
FTSV
Forty Seven
0.00
N/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$108.0710.07% Upside
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.13
Hold$4.78535.83% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4415.48% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0057.42% Upside

Current Analyst Ratings Breakdown

Latest INSM, PCRX, FTSV, ZYME, and IRWD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.00
7/3/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$13.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forty Seven Inc stock logo
FTSV
Forty Seven
$15.68M293.33N/AN/A$7.52 per share12.70
Insmed, Inc. stock logo
INSM
Insmed
$363.71M51.21N/AN/A$1.60 per share61.36
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$317.68M0.38$0.05 per share15.21($1.88) per share-0.40
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$702.77M1.51$4.32 per share5.30$16.86 per share1.36
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M9.95N/AN/A$6.63 per share2.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forty Seven Inc stock logo
FTSV
Forty Seven
-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$880K-$0.20N/A3.01N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A8.91N/A-14.78%13.78%7.00%7/29/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)

Latest INSM, PCRX, FTSV, ZYME, and IRWD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52N/AN/AN/A$17.18 millionN/A
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
5/7/2025Q1 2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forty Seven Inc stock logo
FTSV
Forty Seven
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forty Seven Inc stock logo
FTSV
Forty Seven
N/A
14.81
14.81
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
3.34
3.34
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Forty Seven Inc stock logo
FTSV
Forty Seven
71.77%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Forty Seven Inc stock logo
FTSV
Forty Seven
37.40%
Insmed, Inc. stock logo
INSM
Insmed
3.00%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
12.70%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Forty Seven Inc stock logo
FTSV
Forty Seven
5748.16 millionN/ANot Optionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
220161.82 million141.27 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.68 million67.56 millionOptionable

Recent News About These Companies

Zymeworks’ zanidatamab approved in China

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Forty Seven stock logo

Forty Seven NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Insmed stock logo

Insmed NASDAQ:INSM

$98.18 +1.52 (+1.57%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$98.18 0.00 (0.00%)
As of 07/11/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.75 -0.02 (-3.04%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.74 -0.01 (-0.97%)
As of 07/11/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$22.90 -0.79 (-3.33%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$22.90 0.00 (-0.02%)
As of 07/11/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$13.34 -0.32 (-2.34%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$13.48 +0.14 (+1.05%)
As of 07/11/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.